open access
Ovarian carcinosarcoma is a rare subtype of ovarian cancer with poor
clinical outcomes. The low incidence of this disease makes accrual to
large clinical trials challenging. However, studies have shown that
treatment responses in patient-derived xenograft (PDX) models correlate
with matched-patient responses in the clinic, supporting their use for
preclinical testing of standard and novel therapies. An ovarian
carcinosarcoma PDX is presented herein and showed resistance to
carboplatin and paclitaxel (similar to the patient) but exhibited
significant sensitivity to ifosfamide and paclitaxel......
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.